Tiefenbacher Group celebrates Earth Day 2024
We are pleased to inform you that TIEFENBACHER GROUP is successfully on its way to becoming climate neutral by the end of 2025*.Every year, Earth Day provides the keynote for a wide range of…
Tiefenbacher first-to-market launch: Rivaroxaban
Tiefenbacher Pharmaceuticals successfully prepares the launch of the anticoagulant Rivaroxaban.We at Tiefenbacher Pharmaceuticals strongly believe that our high-quality medicines should be affordable…
Tiefenbacher Group welcomes new COO Sandip Tarate
We are pleased to welcome our new COO for AET Laboratories, Sandip Tarate, to Tiefenbacher Group.Sandip has joined our site in Hyderabad, India, with 23+ years of extensive experience in the…
Tiefenbacher Group raises awareness of autism
Tiefenbacher Group raises awareness of autism on today's World Autism Awareness Day.Obviously the aim of World Autism Awareness Day is to draw attention to the needs and lifelong…
Tiefenbacher Group greetings from DCAT Week!
Today is the last day of one of the world´s most important pharma events – DCATWeek in New York City!Our Tiefenbacher Group team sends greetings and their impressions of DCAT Week from…
Tiefenbacher Group awarded EcoVadis silver medal!
We are excited to share that Tiefenbacher API + Ingredients has been awarded the EcoVadis Silver Medal!EcoVadis is the world’s largest provider of business sustainability ratings. The EcoVadis…
Tiefenbacher Group celebrates International Women’s Day
Today Tiefenbacher Group celebrates International Women's Day, that's why we would like to introduce you to two valuable female employees from our company.Get to know the women who are working at…
Tiefenbacher Group on awareness for rare disease day
Tiefenbacher Group draws attention to Rare Disease Day.Today we are focusing on awareness and generating change for the 300 million people worldwide living with rare diseases. Treatment for many rare…
Tiefenbacher Group supports Pharmacists in Ukraine
Tiefenbacher Group supporting people in Ukraine by donating to Pharmacists without borders.The 24 February 2024, marks the second anniversary of the brutal Russian war against a sovereign Ukraine.…
Tiefenbacher Group renovation of headquarters
Tiefenbacher Group keeping you updated on the ongoing renovation of our headquarters at the Port of Hamburg in Germany.Tiefenbacher Group is happy to present some of the results of the remodelling…
Tiefenbacher Pharmaceuticals wishes a Happy Chinese New Year!
The Chinese New Year is almost here.On the 10th of February, people around the world celebrate the Chinese New Year. They honour this day with carnival events, family gatherings, parades, traditional…
Tiefenbacher Pharmaceuticals together against blood cancer
Tiefenbacher Pharmaceuticals and DKMS together against blood cancer!First of all we are pleased to inform you that we have initiated a DKMS registration event during the last week in our headquartes…
Tiefenbacher Pharmaceuticals speaks out against racism and supports diversity
TIEFENBACHER PHARMACEUTICALS speaks out against racism and supports diversity - as a healthcare company, we are committed to stopping racism and discrimination, wherever we canTiefenbacher embraces…
AET Laboratories 20th anniversary celebration
Last year, we not only celebrated Tiefenbacher Group´s 60th anniversary in Hamburg, but also the 20th anniversary of AET Laboratories – our development and manufacturing site in Hyderabad, India.…
Tiefenbacher Pharmaceuticals wishes you a happy new year!
TIEFENBACHER PHARMACEUTICALS, a part of TIEFENBACHER GROUP: As 2023 draws to a close, we would like to share some of the year's highlights with you. This year we not only had our 60th…
Tiefenbacher New Market Launch: Rivaroxaban in Canada
Tiefenbacher Pharmaceuticals successfully launches the anticoagulant Rivaroxaban on day one in CanadaWe at Tiefenbacher Pharmaceuticals strongly believe that our high-quality medicines should be…
Tiefenbacher Pharmaceuticals at CPhI Barcelona 2023
Tiefenbacher Pharmaceuticals, a part of Tiefenbacher Group, at CPHI Barcelona 2023
60 years of pioneering healthcare at Tiefenbacher Group!
Tiefenbacher Pharamaceuticals – a part of Tiefenfacher Group:60 years of Pioneering HealthcareTiefenbacher Group says “Thank you” to our colleagues from our three main…
Tiefenbacher Group 60 years anniversary celebration!
Tiefenbacher Pharamaceuticals – a part of Tiefenfacher Group:60 years anniversary celebrations We are very happy to announce that Tiefenbacher Group celebrates its 60th anniversary this…
Tiefenbacher Pharmaceuticals launch of generic Teriflunomide
New market launch by Tiefenbacher Pharmaceuticals: Generic version of Teriflunomide in more than 20 European countries.We are thrilled to announce that we have successfully prepared a day one launch…
State-of-the-art R&D facilities for powerful drug development
State-of-the-art R&D facilities for powerful drug development and manufacturing. New technology for generic, valued added, and innovative pharmaceuticalsWe, at Tiefenbacher Group, go beyond…
Tiefenbacher Pharmaceuticals Social Day 2023: Community Engagement
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group: Social Day 2023 – contribution through our social and community engagement in HamburgTiefenbacher Pharmaceuticals employees get involved in…
OYSTA: NEW WEBSITE ONLINE!
OYSTA: New website online – combining pharmaceuticals with e-health technology We are happy to announce that we have launched a new web page for OYSTA – an innovative healthcare brand…
Tiefenbacher: Approval of manufacturing and laboratory facilities by Saudi Food and Drug Authority (SFDA)
Tiefenbacher: Own manufacturing and laboratory facilities successfully registered by the Saudi Food and Drug Authority (SFDA) for GCC regionThe SFDA approves Tiefenbacher facilities! We are happy to…
TIEFENBACHER GROUP is committed to becoming climate neutral
Tiefenbacher Group is committed to becoming climate neutral by the end of 2025We are pleased to share that TIEFENBACHER GROUP is committed to becoming climate neutral by the end of 2025*. As a…
Tiefenbacher: Renovating Headquarters in Hamburg
Tiefenbacher Pharmaceutical, a part of Tiefenbacher Group:Renovating Headquarters in Hamburg /Germany – an agile, open-plan work spaceDid you know that Tiefenbacher Group is currently…
TIEFENBACHER PHARMACEUTICALS AT DCAT 2023
Tiefenbacher Pharmaceuticals – a part of Tiefenbacher Group – at DCAT 2023: Thanks for meeting us in New York City!DCAT week – one of the world´s most important pharma events – has…
Tiefenbacher Pharmaceuticals New market launch: antihistamine Bilastine
New Market Launch: Tiefenbacher Pharmaceuticals successfully launches the antihistamine Bilastine for a market entry as over-the-counter (OTC) medicine in GermanyThe allergy season is starting.…
TIEFENBACHER GROUPS: Registration of manufacturing sites by UAE Ministry of Health
Tiefenbacher manufacturing sites have been successfully registered by the United Arab Emirates Ministry of HealthWe are excited to announce that our two manufacturing sites at AET Laboratories in…
Tiefenbacher Pharmaceuticals: World Cancer Day 2023
Tiefenbacher Pharmaceuticals marks 'World Cancer Day 2023' to increase awareness prevention throughout media togetherTIEFENBACHER joined to harness the power of social media to raise awareness on…
TIEFENBACHER PHARMACEUTICALS WISHES A HEALTHY NEW YEAR 2023
Tiefenbacher Pharmaceuticals – a part of Tiefenbacher Group:Health New Year 2023 From all over the world, we wish you a happy and healthy New Year 2023! In order to serve more than 80…
Tiefenbacher Pharmaceuticals generic launch: Psoriasis medication Apremilast
New Market Launch: TIEFENBACHER PHARMACEUTICALS successfully launches generic version of the psoriasis medication Apremilast in CanadaWe at Tiefenbacher Pharmaceuticals strive to make our…
TIEFENBACHER PHARMACEUTICALS New market launch: Abiraterone/Prednisolone
Tiefenbacher Pharmaceuticals successfully launches generic versions of Abiraterone and value-added product Abiraterone/Prednisolone, Prostate CancerWe at Tiefenbacher Pharmaceuticals aim to improve…
Tiefenbacher Pharmaceuticals: Thanks for visiting us at CPhI 2022 in Frankfurt!
Tiefenbacher Pharmaceuticals – a part of Tiefenbacher Group: CPhI 2022, the world`s leading pharma event, has just come to an end. It was wonderful to meet our valued customers and…
TIEFENBACHER GROUP opens new manufacturing site in Cyprus /Europe
Tiefenbacher Pharmaceuticals – a part of Tiefenbacher Group Did you know that TIEFENBACHER GROUP heavily invests in its in-house production capacities for high-quality pharmaceuticals?…
TIEFENBACHER PHARMACEUTICALS New market launch: Anticoagulant medicine Apixaban
New Market Launch: TIEFENBACHER PHARMACEUTICALS successfully launches generic version of the anticoagulant medicine Apixaban in CanadaWe at TIEFEENBACHER PHARMACEUTICALS are driven by enabling people…
Meet TIEFENBACHER PHARMACEUTICALS at CPHI 2022 in Frankfurt /Germany
Tiefenbacher Pharmaceuticals – a part of Tiefenbacher Group: Meet us at CPHI in Frankfurt!We are very excited to meet our valued customers and partners once again on CPHI 2022, the world’s leading…
TIEFENBACHER PHARMACEUTICALS New market launch: Diabetis medicine Vildagliptin / Metformin
NEW Market Launch: TIEFENBACHER PHARMACEUTICALS successfully launches generic version of the diabetes medicine Vildagliptin and Vildagliptin /Metformin in AfricaWe at Tiefenbacher Pharmaceuticals…
Tiefenbacher: Employee benefits and climate reduction goals
Environmentally friendly and health-promoting: TIEFENBACHER GROUP offers bike leasing to employees
TIEFENBACHER PHARMACEUTICALS New market launch: TERIFLUNOMIDE
New market launch: TIEFENBACHER PHARMACEUTICALS successfully launches first generic version of the Multiple Sclerosis (MS) medicine Teriflunomide in CandaWe at TIEFEENBACHER PHARMACEUTICALS strive to…
TIEFENBACHER GROUP OPENS NEW SITE FOR HIGHLY POTENT DRUGS IN INDIA
Tiefenbacher continuously expand in novel technologies and capabilities to improve quality and boost productivity of better healthcareTiefenbacher Group is excited to announce the ceremonious opening…
WORLD HEALTH DAY @ TIEFENBACHER PHARMACEUTICALS
World Health Day is on the 7th of April each year – this day marks the anniversary of the World Health Organization which was founded in 1948.Today we celebrate World Health Day. This Day marks the…
TIEFENBACHER GROUP AT DCAT 2022 – THANKS FOR MEETING US IN NEW YORK CITY!
One of the world´s most important pharma events – DCAT week in New York City – has just come to an end. It was four very successful and inspiring days for TIEFENBACHER GROUP presenting…
TIEFENBACHER PHARMACEUTICALS New market launch: LACOSAMIDE
TIEFENBACHER PHARMACEUTICALS successfully launches generic version of the epilepsy medicine Lacosamide in AustraliaWe at TIEFEENBACHER PHARMACEUTICALS strongly believe that our high-quality medicines…
TIEFENBACHER PHARMACEUTICALS stands with Ukraine
Peace and freedom for Ukraine: We, a pharmaceutical company in Europe, stand in solidarity with the people in UkraineTo us at Tiefenbacher Pharmaceuticals, it is unbearable to witness what is…
MEET TIEFENBACHER PHARMACEUTICALS DURING DCAT WEEK IN NEW YORK CITY 2022
Meet TIEFENBACHER PHARMACEUTICALS during DCAT week in New York City 2022 from 21-24th march!Reach out to TIEFENBACHER PHARMACEUTICALS at DCAT in New York City from 21-24th March and discover our…
TIEFENBACHER GROUP WISHES A HAPPY AND HEALTHY NEW YEAR 2022 FROM ALL OVER THE WORLD!
We at TIEFENBACHER GROUP wish you a happy and healthy new year 2022 from all over the world! Please watch the short video for our new year greetings from our colleagues from our three…
TIEFENBACHER GROUP enlarges its manufacturing facilities for powerful drug production
Driving efficiency is our key – TIEFENBACHER GROUP enlarges its manufacturing facilities in India and Cyprus for powerful drug productionDid you know that TIEFENBACHER GROUP heavily invests in its…
TIEFENBACHER PHARMACEUTICALS at CPhI 2021 – thanks for visiting us in Milano!
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, at CPHI in Milano With over 1,300 exhibitors and more than 20,000 attendees the world`s leading pharma eventt CPHI has just…
TIEFENBACHER GROUP: New school building in India
Social Responsibility and Community EngagementAt TIEFENBACHER GROUP giving back to society is important to us: New school building in India As a value-driven healthcare company,…
TIEFENBACHER PHARMACEUTICALS at CPhI in Milan 2021
Reach out to TIEFENBACHER PHARMACEUTICALS at CPHI in Milan 2021 and discover our latest innovations to make pharmaceuticals more affordable, more available, and better than before.“Nothing can…
TIEFENBACHER PHARMACEUTICALS New market launch: antihistamine Bilastine
We at TIEFEENBACHER PHARMACEUTICALS strongly believe that our high-quality medicines should be affordable for all patients irrespective of their income level or nationality. That´s why Tiefenbacher…
New agreement expands collaboration between OnDosis and TIEFENBACHER GROUP
Innovative Healthcare Pharmaceuticals with e-health technology in the ADHD field, rare diseases, and transplantation medicineSwedish Life science company OnDosis and German B2B pharmaceutical company…
TIEFENBACHER PHARMACEUTICALS supports Post COVID-19 with Posaconazole against Black Fungus (Mucormycosis)
Black Fungus (Mucormycosis) is dramatically spreading in India connected to the extensive 2nd COVID-19 wave. The highly life-threatening disease usually occurs as a rare disease in immunocompromised…
TIEFENBACHER GROUP announces global launch of TIEFENBACHER MEDICAL DEVICES
After more than five years in operation, TIEFENBACHER GROUP will transfer its medical device business into a new stand-alone company: TIEFENBACHER MEDICAL DEVICES The launch follows TIEFENBACHER…
TIEFENBACHER PHARMACEUTICALS: Launch generic version of Teriflunomide, Multiple Sclerosis (MS)
Tiefenbacher Pharmaceuticals announces global launch of Teriflunomide – making multiple sclerosis therapy more affordable and better available worldwideTiefenbacher Pharmaceuticals has successfully…
AET Pharma US Inc., Part of Tiefenbacher, approval of Abbreviated New Drug Application (ANDA) for Posaconazole
AET Pharma US Inc., a part of TIEFENBACHER GROUP, announces successful approval of Abbreviated New Drug Application (ANDA) for PosaconazoleOn 1st February 2021, AET Pharma US Inc, part of…
TIEFENBACHER PHARMACEUTICALS: Launch of Rivaroxaban – an anticoagulant medication (blood thinner)
TIEFENBACHER PHARMACEUTICALS, part of Tiefenbacher Group, is pleased to announce the availability of a registration dossier for the generic of Rivaroxaban 2.5 mg, 10 mg, 15 mg and 20 mg film-coated…
International Brand Relaunch of TIEFENBACHER PHARMACEUTICALS
AET TIEFENBACHER PHARMACEUTICALS: Making pharmaceuticals more affordable, more affordable, and better than before“We are very excited to launch our new AET website, representing the pharmaceutical…
Tiefenbacher Group and OnDosis enter a strategic partnership for game-changing integration of medicines and digital health
Tiefenbacher Group and OnDosis today announced the signing of an extensive co-development agreement for multiple products in the upcoming years. This collaboration strengthens both companies’…
